Spots Global Cancer Trial Database for everolimus
Every month we try and update this database with for everolimus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| RAD001 Plus Bevacizumab in Metastatic Melanoma | NCT00591734 | Metastatic Mela... | Bevacizumab Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | NCT01229943 | Advanced Pancre... Locally Advance... Pancreatic Gast... Pancreatic Neur... Pancreatic Neur... Pancreatic Vipo... | Bevacizumab Everolimus Octreotide Acet... | 18 Years - | National Cancer Institute (NCI) | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers | NCT01624766 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali... | Anakinra Denosumab Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) | NCT02338570 | Renal Cell Carc... | Everolimus | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Everolimus in Treating Patients With Recurrent Low-Grade Glioma | NCT00823459 | Adult Diffuse A... Adult Mixed Gli... Adult Oligodend... Adult Subependy... Recurrent Adult... | Everolimus Archival Tissue... | 18 Years - | University of California, San Francisco | |
| Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00805129 | Bladder Cancer Metastatic Tran... | Everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | NCT03114527 | Soft Tissue Sar... | Ribociclib Everolimus | 18 Years - | Fox Chase Cancer Center | |
| An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis | NCT02205515 | Carcinoma, Neur... | Everolimus | 18 Years - | Sunnybrook Health Sciences Centre | |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | NCT03355794 | Diffuse Intrins... Malignant Gliom... High Grade Glio... Bithalamic High... Brainstem Gliom... Glioblastoma Anaplastic Astr... | ribociclib Everolimus | 12 Months - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | NCT02511639 | Breast Cancer M... | Everolimus Aromatase Inhib... | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy | NCT01805271 | Primary Non-met... Who Remain Dise... | Everolimus Placebo | 18 Years - | UNICANCER | |
| A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00622258 | Non-Hodgkin's L... | Everolmus | 20 Years - | Novartis | |
| Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma | NCT01491672 | Metastatic Rena... | RAD001 | 18 Years - | Novartis | |
| LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | NCT02985125 | Metastatic Panc... | LEE011 Everolimus | 18 Years - | Georgetown University | |
| Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | NCT01231399 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Stage IV Esopha... Stage IV Gastri... | fluorouracil leucovorin calc... oxaliplatin everolimus laboratory biom... immunohistochem... microarray anal... | 19 Years - | City of Hope Medical Center | |
| Everolimus in Treating Patients With Recurrent Low-Grade Glioma | NCT00823459 | Adult Diffuse A... Adult Mixed Gli... Adult Oligodend... Adult Subependy... Recurrent Adult... | Everolimus Archival Tissue... | 18 Years - | University of California, San Francisco | |
| Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) | NCT02809404 | Breast Cancer Renal Cell Carc... | Everolimus | 18 Years - | Radboud University Medical Center | |
| Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | NCT02616848 | Triple Negative... | Everolimus Eribulin | 18 Years - | Istituti Ospitalieri di Cremona | |
| Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) | NCT00789828 | Tuberous Sclero... Subependymal Gi... | Everolimus Placebo | - | Novartis | |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | NCT01281865 | Adult Synovial ... Recurrent Adult... Stage III Adult... Stage IV Adult ... | diagnostic labo... everolimus imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00124280 | Non-small-cell ... | RAD001 | 18 Years - | Novartis | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00124280 | Non-small-cell ... | RAD001 | 18 Years - | Novartis | |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | NCT01582191 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali... | Everolimus Laboratory Biom... Pharmacological... Vandetanib | - | M.D. Anderson Cancer Center | |
| Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | NCT01035229 | Carcinoma | Everolimus Everolimus Plac... Best Supportive... | 18 Years - | Novartis | |
| Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | NCT00782626 | Glioma Low-grade Gliom... Astrocytoma | everolimus | 3 Years - 21 Years | Dana-Farber Cancer Institute | |
| Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | NCT02228681 | Advanced, Persi... | Everolimus Tamoxifen Letrozole Medroxyprogeste... | 18 Years - | GOG Foundation | |
| Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT00516412 | Lymphoma | everolimus molecular respo... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy | NCT00727207 | Lymphoma | everolimus | 40 Years - | Technical University of Munich | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) | NCT00651482 | Kidney Neoplasm... Kidney (Renal C... | Everolimus Bevacizumab | 18 Years - | Stanford University | |
| Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | NCT00762632 | Acute Myeloid L... | NILOTINIB EVEROLIMUS | 18 Years - | Technical University of Munich | |
| AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme | NCT00107237 | Brain and Centr... | AEE788 everolimus | 18 Years - | Novartis | |
| Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | NCT03154281 | Breast Cancer Ovarian Cancer | niraparib everolimus | 18 Years - | Avera McKennan Hospital & University Health Center | |
| Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | NCT02842749 | Pancreatic Neur... | everolimus | 18 Years - | Novartis | |
| Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT01231659 | Postmenopausal ... Locally Advance... Metastatic Brea... | Everolimus Letrozole | 18 Years - | Novartis | |
| A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | NCT01797523 | Endometrial Can... | Metformin Letrozole Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) | NCT03493165 | Uterine Sarcoma | Everolimus | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) | NCT02338570 | Renal Cell Carc... | Everolimus | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine | NCT00560963 | Advanced or Met... | everolimus | 18 Years - | Novartis | |
| Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma | NCT01028638 | Metastatic Rena... | 89Zr-bevacizuma... | 18 Years - | University Medical Center Groningen | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary | NCT00936702 | Carcinoma of Un... | carboplatin everolimus paclitaxel | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | NCT02776644 | Renal Cell Carc... | - | Pfizer | ||
| Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | NCT01582009 | Clear Cell Rena... Recurrent Renal... Stage III Renal... Stage IV Renal ... | panobinostat everolimus laboratory biom... pharmacological... liquid chromato... mass spectromet... enzyme-linked i... immunohistochem... | 18 Years - | Roswell Park Cancer Institute | |
| Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | NCT01281865 | Adult Synovial ... Recurrent Adult... Stage III Adult... Stage IV Adult ... | diagnostic labo... everolimus imatinib mesyla... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | NCT00402662 | Metastatic Mela... | everolimus Imatinib | 18 Years - | Yale University | |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | NCT01698918 | Hormone Recepto... | Everolimus Letrozole Exemestane Alcohol-free de... Standard of car... | 18 Years - | Novartis | |
| Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | NCT01009801 | Liver Cancer | doxorubicin-elu... everolimus placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus | NCT01715935 | Clear-cell Rena... Clear-cell Meta... | Everolimus | 18 Years - | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| Itacitinib + Everolimus in Hodgkin Lymphoma | NCT03697408 | Classical Hodgk... | Itacitinib Everolimus | 18 Years - | University of Pennsylvania | |
| Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | NCT02069093 | Advanced Breast... | Dexamethasone b... Everolimus Exemestane | 18 Years - | Novartis | |
| Everolimus in Treating Patients With Recurrent Low-Grade Glioma | NCT00823459 | Adult Diffuse A... Adult Mixed Gli... Adult Oligodend... Adult Subependy... Recurrent Adult... | Everolimus Archival Tissue... | 18 Years - | University of California, San Francisco | |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | NCT01185366 | Kidney Cancer | Everolimus Sunitinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | NCT01677390 | Renal Cell Carc... | SGN-75 everolimus | 18 Years - | Seagen Inc. | |
| Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | NCT00411619 | Tuberous Sclero... Subependymal Gi... | Everolimus | 3 Years - | Children's Hospital Medical Center, Cincinnati | |
| Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | NCT02454478 | Carcinoma, Rena... | Lenvatinib Everolimus | 20 Years - | Eisai Inc. | |
| Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) | NCT01266837 | Metastatic Rena... Failure of Exac... | Everolimus | 18 Years - | iOMEDICO AG | |
| Everolimus for Cancer With TSC1 or TSC2 Mutation | NCT02201212 | TSC1 TSC2 Tuberous Sclero... MTOR | Everolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | NCT02450175 | Neoplasm | Everolimus Letrozole | 18 Years - | Sinai Hospital of Baltimore | |
| A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis | NCT01954693 | Tuberous Sclero... | Placebo Everolimus (RAD... | 16 Years - 60 Years | Cardiff University | |
| Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | NCT01239342 | Metastatic Kidn... Recurrent Renal... Stage III Renal... Stage IV Renal ... | Akt Inhibitor M... Everolimus Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| RAD001 Plus Bevacizumab in Metastatic Melanoma | NCT00591734 | Metastatic Mela... | Bevacizumab Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure | NCT00570921 | Breast Cancer | Everolimus Fulvestrant | 45 Years - | University of Kentucky | |
| Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer | NCT02504892 | Renal Cancer Birt-Hogg-Dube ... | Everolimus | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | NCT01014351 | Metastatic Mela... | Paclitaxel Carboplatin Everolimus | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone | NCT01263951 | Differentiated ... | Everolimus Sorafenib | 18 Years - 89 Years | Thomas Jefferson University | |
| A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | NCT03070301 | Neuroendocrine ... | LEE011 everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | NCT04185883 | Advanced Solid ... Kirsten Rat Sar... | Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pe... Atezolizumab Palbociclib MVASI® (bevaciz... TNO155 IV Chemotherapy... IV Chemotherapy... BI 1701963 AMG 404 Everolimus | 18 Years - 100 Years | Amgen | |
| 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors | NCT01338090 | Neuroendocrine ... | 89Zr-bevacizuma... Everolimus | 18 Years - 80 Years | University Medical Center Groningen | |
| Exemestane-RAD001-Metformin | NCT01627067 | Breast Cancer | Everolimus Exemestane Metformin | 18 Years - | M.D. Anderson Cancer Center | |
| Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | NCT02450175 | Neoplasm | Everolimus Letrozole | 18 Years - | Sinai Hospital of Baltimore | |
| Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT00869999 | Diffuse Large B... | Everolimus rituximab | 18 Years - | Massachusetts General Hospital | |
| Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus | NCT02539459 | Sporadic Angiom... | Everolimus | 18 Years - | Fox Chase Cancer Center | |
| Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02254239 | Recurrent Hodgk... Refractory Hodg... | Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological... | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
